Tokushima University / Educator and Researcher Directory --- Fujihara, Toshitaka

Field of Study

Subject of Study

Book / Paper

Academic Paper (Judged Full Paper):

1.	Mai Azumi, Yoshifumi Mizobuchi, Nobuto Nakanishi, Kohhei Nakajima, Keijiro Hara, Toshitaka Fujihara, Manabu Ishihara, Jun Oto and Yasushi Takagi : Value of the Acute Physiology and Chronic Health Evaluation II (APACHE II) score in predicting hospital mortality for postoperative brain tumor patients in intensive care units in Japan: A retrospective case-control study, Clinical Neurology and Neurosurgery, Vol.244(2024), No.108435, 108435, 2024. (Summary) Acute Physiology and Chronic Health Evaluation II (APACHE II) is based on the data of intensive care unit (ICU) patients and often correlates with disease severity and prognosis. However, no prognostic predictors exist based on ICU admission data for patients with brain tumors, and no studies have reported an association between APACHE II and prognosis in patients with brain tumors. The Japanese Intensive Care Patients Database (JIPAD) was established to improve the quality of care delivered in intensive care medicine in Japan. We used JIPAD to examine factors associated with in-hospital mortality based on available data of postoperative patients with brain tumors admitted to the ICU. Patients aged ≥16 years enrolled in JIPAD between April 2015 and March 2018 after surgical brain tumor resection or biopsy of brain tumors. We examined factors related to outcomes at discharge based on blood tests and medical procedures performed during ICU admission, tumor type, and APACHE II score. Among the 1454 patients (male:female ratio: 1:1.1, mean age: 62 years) in the study, 32 (2.2 %) died during hospital stay. In multivariate analysis, male sex (odds ratio [OR] 2.70, [95 % confidence interval, CI 1.22-6.00]), malignant tumor (OR 2.51 [95 % CI 1.13-5.55]), and APACHE II score ≥15 (OR 2.51 [95 % CI 3.08-14.3]) were significantly associated with in-hospital mortality. By picking up cases with a high risk of in-hospital death at an early stage, it is possible to improve methods of treatment and support for the patient's family. (Keyword) Humans / Male / Female / Middle Aged / Hospital Mortality / APACHE / Japan / Brain Neoplasms / Aged / Intensive Care Units / Retrospective Studies / Case-Control Studies / Adult / Prognosis / Aged, 80 and over / Predictive Value of Tests (Link to Publication Site) ● Publication site (DOI): 10.1016/j.clineuro.2024.108435 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 38996799 ● Summary page in Scopus @ Elsevier: 2-s2.0-85198060266 (DOI: 10.1016/j.clineuro.2024.108435, PubMed: 38996799, Elsevier: Scopus)
2.	Yoshiteru Tada, Toshitaka Fujihara, Kenji Shimada, Nobuaki Yamamoto, Hiroki Yamazaki, Yuishin Izumi, Masafumi Harada, Yasuhisa Kanematsu and Yasushi Takagi : Seizure types associated with negative arterial spin labeling and positive diffusion-weighted imaging on peri-ictal magnetic resonance imaging, Journal of the Neurological Sciences, Vol.436, 1-8, 2022. (Summary) Arterial spin labeling (ASL) and diffusion-weighted imaging (DWI) are useful for assessing hyperperfusion and cytotoxic edema, respectively, caused by acute seizures. This study investigated the clinical characteristics associated with normal ASL findings and DWI abnormalities in patients with acute seizures. Overall, 41 patients with ASL and DWI images that were obtained within 48 h of focal onset seizure diagnosis, due to epilepsy or acute symptomatic seizures, were divided into groups based on initial ASL findings (ASL-negative vs. ASL-positive), and DWI abnormalities (DWI-negative vs. DWI-positive). The diagnosis was made based on seizure semiology, electroencephalography, and conventional imaging modalities. ASL and DWI abnormalities were based on visual assessment. Of the 41 patients, eight (19.5%) displayed normal ASL findings. The proportion of patients with focal aware seizures (FAS) was significantly higher among ASL-negative patients (62.5%) than that in ASL-positive patients (15.2%); the proportion of patients with focal impaired awareness seizures (FIAS) was significantly lower among ASL-negative patients (12.5%) than that among ASL-positive patients (57.6%). Hyperintensity findings on DWI were observed in 12 patients (29.3%, DWI-positive). The proportion of patients with FIAS was significantly higher among DWI-positive patients (75.0%) than that among DWI-negative patients (37.9%). Multivariate analysis revealed that FAS and FIAS were associated with normal ASL findings (odds ratio [OR]: 21.37, P = 0.010) and DWI abnormalities (OR = 6.11, P = 0.028). A diagnosis of seizures should not be excluded based on normal ASL findings, especially in patients with FAS. FIAS may be a risk factor for neuronal damage caused by seizure activity. (Link to Publication Site) ● Publication site (DOI): 10.1016/j.jns.2022.120223 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 35279594 ● Summary page in Scopus @ Elsevier: 2-s2.0-85126008460 (DOI: 10.1016/j.jns.2022.120223, PubMed: 35279594, Elsevier: Scopus)
3.	Yoshifumi Mizobuchi, Kohhei Nakajima, Toshitaka Fujihara, Mai Azumi and Yasushi Takagi : Development of a Navigation-guided Fence-post Catheter for Brain Tumor Resection, The Journal of Medical Investigation : JMI, Vol.69, No.1,2, 117-119, 2022. (Summary) Navigation system devices have been developed to allow precise resection of brain tumor. The fence-post catheter techniques that use a navigation system have been used in many neurosurgery centers. However, an exclusive catheter for the fence-post catheter techniques have not been made, and substituted silicon tube of the cerebral ventricle drainage or a Nelaton catheter is widely used. In this brief technical note, we describe a new fence-post catheter with steel tip device that was designed for more precise tissue resection and is useful in tumor resection. The newly designed fence-post catheter helps to visually gauge the accurate depth from the tumor bottom during tumor resection. Furthermore, the catheter tip has moderate weight and is made of a non-magnetic material. Using our fence-post catheter, which has a metal part at the tip of the tube (length, 13 mm), operators can clearly notice that they are getting closer to base of the tumor by checking the metal part during the resection of deep tumors. Our newly developed fence-post tube enables easy confirmation of the distance to deep-tissue regions and improves the degree of safety during tumor removal. J. Med. Invest. 69 : 117-119, February, 2022. (Keyword) Brain / Brain Neoplasms / Catheters / Glioma / Humans / Neurosurgical Procedures (Tokushima University Institutional Repository) ● Metadata: 117022 (Link to Publication Site) ● Publication site (DOI): 10.2152/jmi.69.117 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 35466132 ● Summary page in Scopus @ Elsevier: 2-s2.0-85128801353 (Tokushima University Institutional Repository: 117022, DOI: 10.2152/jmi.69.117, PubMed: 35466132, Elsevier: Scopus)
4.	Kenji Shono, Yoshifumi Mizobuchi, Izumi Yamaguchi, Kohhei Nakajima, Yuri Fujiwara, Toshitaka Fujihara, Keiko Kitazato, Kazuhito Matsuzaki, Yoshihiro Uto, Oltea Sampetrean, Hideyuki Saya and Yasushi Takagi : Elevated cellular PpIX potentiates sonodynamic therapy in a mouse glioma stem cell-bearing glioma model by downregulating the Akt/NF-κB/MDR1 pathway., Scientific Reports, Vol.11, No.1, 2021. (Summary) Glioblastoma (GBM) has high mortality rates because of extreme therapeutic resistance. During surgical resection for GBM, 5-aminolevulinic acid (5-ALA)-induced protoporphyrin IX (PpIX) fluorescence is conventionally applied to distinguish GBM. However, surgical intervention is insufficient for high invasive GBM. Sonodynamic therapy (SDT) combined with low-intensity ultrasonication (US) and PpIX, as a sonosensitizer, is an emerging and promising approach, although its efficacy is limited. Based on our previous study that down-regulation of multidrug resistant protein (MDR1) in GBM augmented the anti-tumor effects of chemotherapy, we hypothesized that elevation of cellular PpIX levels by down-regulation of MDR1 enhances anti-tumor effects by SDT. In high invasive progeny cells from mouse glioma stem cells (GSCs) and a GSC-bearing mouse glioma model, we assessed the anti-tumor effects of SDT with a COX-2 inhibitor, celecoxib. Down-regulation of MDR1 by celecoxib increased cellular PpIX levels, as well as valspodar, an MDR1 inhibitor, and augmented anti-tumor effects of SDT. MDR1 down-regulation via the Akt/NF-κB pathway by celecoxib was confirmed, using an NF-κB inhibitor, CAPÉ. Thus, elevation of cellar PpIX by down-regulation of MDR1 via the Akt/NF-κB pathway may be crucial to potentiate the efficacy of SDT in a site-directed manner and provide a promising new therapeutic strategy for GBM. (Keyword) ATP Binding Cassette Transporter, Subfamily B, Member 1 / Aminolevulinic Acid / Animals / Cell Line, Tumor / Down-Regulation / Glioblastoma / Glioma / Male / Mice / Mice, Inbred C57BL / NF-kappa B / Neoplastic Stem Cells / Photosensitizing Agents / Proto-Oncogene Proteins c-akt / Protoporphyrins / Signal Transduction / Ultrasonic Therapy (Tokushima University Institutional Repository) ● Metadata: 116448 (Link to Publication Site) ● Publication site (DOI): 10.1038/s41598-021-93896-0 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 34301977 ● Search Scopus @ Elsevier (PMID): 34301977 ● Search Scopus @ Elsevier (DOI): 10.1038/s41598-021-93896-0 (Tokushima University Institutional Repository: 116448, DOI: 10.1038/s41598-021-93896-0, PubMed: 34301977)
5.	Kenji Shimada, Yoko Yamamoto, Takeshi Miyamoto, Shu Sogabe, Toshitaka Fujihara, Kohhei Nakajima, Yoshifumi Mizobuchi, Yasuhisa Kanematsu and Yasushi Takagi : Efficacy of Intra-arterial Indocyanine Green Videoangiography in Hemangioblastoma Surgery: A Case Report., NMC Case Report Journal, Vol.8, No.1, 295-300, 2021. (Summary) Intravenous indocyanine green (ICG) videoangiography is reportedly useful for vascular neurosurgery, and for treating hemangioblastoma due to its high vascularity. Videoangiography obtained after intra-arterial ICG injection has emerged as a more useful option than that after intravenous injection. This report offers the first description of a case of hemangioblastoma successfully treated using intra-arterial ICG videoangiography, and describes the efficacy of this technique. A 20-year-old man presented with progressive cerebellar ataxia and dysphagia. Magnetic resonance imaging (MRI) revealed an enhanced solid tumor in the medulla oblongata. Digital subtraction angiography (DSA) showed a highly vascularized tumor. Surgery was performed to remove the tumor in a hybrid operating room. A catheter was introduced into the vertebral artery (VA) for intra-arterial ICG videoangiography. Superficial feeders and drainers were identified and flow dynamic changes in the tumor were assessed by intra-arterial ICG videoangiography. The tumor was removed after confirming lack of flow in the drainer. Intra-arterial ICG videoangiography was more useful than intravenous ICG videoangiography in hemangioblastoma surgery for identifying feeders and drainers and assessing flow dynamics in the tumor. Use of Flow 800 made these findings simpler and easier to evaluate. (Link to Publication Site) ● Publication site (DOI): 10.2176/nmccrj.cr.2020-0281 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 35079478 ● Search Scopus @ Elsevier (PMID): 35079478 ● Search Scopus @ Elsevier (DOI): 10.2176/nmccrj.cr.2020-0281 (DOI: 10.2176/nmccrj.cr.2020-0281, PubMed: 35079478)
6.	Kohhei Nakajima, Yoshifumi Mizobuchi, Toshitaka Fujihara, Mai Azumi and Yasushi Takagi : Continued-Maintenance Therapy with High-dose Methotrexate Improves Overall Survival of Patients with Primary Central Nervous System Lymphoma., The Journal of Medical Investigation : JMI, Vol.68, No.3.4, 286-291, 2021. (Summary) In 3-year overall survival (OS) there was a statistically significant difference between the two groups [controls : 33.1% (95%, CI 12.4 - 55.7%) ; maintenance group : 74.9% (95%, CI 55.6 - 86.7%) (p < 0.02)]. Conclusion : The induction of HD-MTX based chemotherapy followed by continued-maintenance HD-MTX monotherapy improved OS compared with chemoradiotherapy consisting of HD-MTX followed by WBRT. J. Med. Invest. 68 : 286-291, August, 2021. (Keyword) Aged / Antineoplastic Combined Chemotherapy Protocols / Central Nervous System / Central Nervous System Neoplasms / Humans / Lymphoma, Non-Hodgkin / Methotrexate / Retrospective Studies (Tokushima University Institutional Repository) ● Metadata: 116496 (Link to Publication Site) ● Publication site (DOI): 10.2152/jmi.68.286 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 34759146 ● Search Scopus @ Elsevier (PMID): 34759146 ● Search Scopus @ Elsevier (DOI): 10.2152/jmi.68.286 (Tokushima University Institutional Repository: 116496, DOI: 10.2152/jmi.68.286, PubMed: 34759146)
7.	Kenji Shono, Izumi Yamaguchi, Yoshifumi Mizobuchi, Hiroshi Kagusa, Akiko Sumi, Toshitaka Fujihara, Kohhei Nakajima, T Keiko Kitazato, Kazuhito Matsuzaki, Hideyuki Saya and Yasushi Takagi : Downregulation of the CCL2/CCR2 and CXCL10/CXCR3 axes contributes to antitumor effects in a mouse model of malignant glioma., Scientific Reports, Vol.10, No.1, 2020. (Summary) microglia. In GSCs, celecoxib inhibited Ccl2 and Cxcr3 expression in a nuclear factor-kappa B-dependent manner but not Ccr2 and CxcL10. Moreover, Ccl2 silencing resulted in decreased GSC viability. These results suggest that celecoxib-mediated regulation of the CCL2/CCR2 and CXCL10/ CXCR3 axes may partially contribute to glioma-specific antitumor effects. (Keyword) Animals / Antineoplastic Agents / Cell Line / Chemokine CCL2 / Chemokine CXCL10 / Disease Models, Animal / Down-Regulation / Glioma / Humans / Male / Mice / Mice, Inbred C57BL / Microglia / Receptors, CCR2 / Receptors, CXCR3 / Stem Cells / Tumor Microenvironment (Tokushima University Institutional Repository) ● Metadata: 117722 (Link to Publication Site) ● Publication site (DOI): 10.1038/s41598-020-71857-3 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 32943658 ● Search Scopus @ Elsevier (PMID): 32943658 ● Search Scopus @ Elsevier (DOI): 10.1038/s41598-020-71857-3 (Tokushima University Institutional Repository: 117722, DOI: 10.1038/s41598-020-71857-3, PubMed: 32943658)
8.	Hiroshi Kagusa, Yoshifumi Mizobuchi, Kohhei Nakajima, Toshitaka Fujihara, Yoshimi Bando and Yasushi Takagi : Metastatic tumor to the orbital cavity from a primary carcinoma of the uterine cervix : a case report., The Journal of Medical Investigation : JMI, Vol.66, No.3,4, 355-357, 2019. (Summary) Metastatic tumors to the orbit of the eye, especially from primary carcinomas of the uterine cervix are very rare. A 64-year-old woman with a history of carcinoma of the uterine cervix presented with right eye pain and blepharoptosis for 2 weeks. Magnetic resonance imaging revealed a mass at the right orbital apex. Surgical extirpation was performed due to severe pain. Postoperative pathology demonstrated a poorly differentiated squamous cell carcinoma. The origin was ultimately considered to be the carcinoma of the uterine cervix. In conclusion, this report describes a rare case of a metastatic tumor at the orbital apex derived from the cervix of the uterus. J. Med. Invest. 66 : 355-357, August, 2019. (Tokushima University Institutional Repository) ● Metadata: 114169 (Link to Publication Site) ● Publication site (DOI): 10.2152/jmi.66.355 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 31656305 ● Search Scopus @ Elsevier (PMID): 31656305 ● Search Scopus @ Elsevier (DOI): 10.2152/jmi.66.355 (Tokushima University Institutional Repository: 114169, DOI: 10.2152/jmi.66.355, PubMed: 31656305)
9.	Yoshifumi Mizobuchi, Kohhei Nakajima, Toshitaka Fujihara, Kazuhito Matsuzaki, Hideo Mure, Shinji Nagahiro and Yasushi Takagi : The risk of hemorrhage in stereotactic biopsy for brain tumors., The Journal of Medical Investigation : JMI, Vol.66, No.3,4, 314-318, 2019. (Summary) Objective : One major complication associated with STB is intratumoral hematoma, which is also the most common cause of morbidity related to permanent paralysis and mortality in STB. The risk of perioperative hemorrhage is generally between 1% and 10%, but this could be an underestimation since it is not common for many neurosurgeons to perform CT scans after uncomplicated STBs. In this study, we describe the incidence of cerebral hemorrhage, including asymptomatic cerebral hemorrhage. Methods : We recently reviewed data on the diagnosis rate and occurrence of complications, including symptomatic and asymptomatic cerebral hemorrhage, in 80 patients who underwent STB at our facility between 2005 and 2014. Results : Histological diagnosis was established for 75 cases (93.8%), glioma was the most frequently encountered tumor. Symptomatic hemorrhage was observed in two cases (2.6%), with the symptoms subsiding within two days. The morbidity and mortality rate was 0%. However, asymptomatic hemorrhages were observed in 23 cases (28.8%). Conclusion : Stereotactic biopsy is a less invasive procedure for obtaining samples of brain tumors for diagnosis. The bleeding of the tissue-resection cavity that includes asymptomatic hemorrhage occurs at a constant rate. It is important to reduce the symptomatic bleeding associated with stereotactic biopsy. J. Med. Invest. 66 : 314-318, August, 2019. (Keyword) Adolescent / Adult / Aged / Aged, 80 and over / Biopsy / Brain / Brain Neoplasms / Cerebral Hemorrhage / Female / Humans / Male / Middle Aged / Stereotaxic Techniques / Young Adult (Tokushima University Institutional Repository) ● Metadata: 114088 (Link to Publication Site) ● Publication site (DOI): 10.2152/jmi.66.314 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 31656296 ● Search Scopus @ Elsevier (PMID): 31656296 ● Search Scopus @ Elsevier (DOI): 10.2152/jmi.66.314 (Tokushima University Institutional Repository: 114088, DOI: 10.2152/jmi.66.314, PubMed: 31656296)
10.	Toshitaka Fujihara, Yoshifumi Mizobuchi, Kohhei Nakajima, Teruyoshi Kageji, Kazuhito Matsuzaki, KT Kitazato, Ryotaro Otsuka, Keijiro Hara, Hideo Mure, Toshiyuki Okazaki, Kazuyuki Kuwayama, Shinji Nagahiro and Yasushi Takagi : Down-regulation of MDR1 by Ad-DKK3 via Akt/NFB pathways augments the anti-tumor effect of temozolomide in glioblastoma cells and a murine xenograft model, Journal of Neuro-Oncology, Vol.139, No.2, 323-332, 2018. (Summary) Glioblastoma multiforme (GBM) is the most malignant of brain tumors. Acquired drug resistance is a major obstacle for successful treatment. Earlier studies reported that expression of the multiple drug resistance gene (MDR1) is regulated by YB-1 or NFκB via the JNK/c-Jun or Akt pathway. Over-expression of the Dickkopf (DKK) family member DKK3 by an adenovirus vector carrying DKK3 (Ad-DKK3) exerted anti-tumor effects and led to the activation of the JNK/c-Jun pathway. We investigated whether Ad-DKK3 augments the anti-tumor effect of temozolomide (TMZ) via the regulation of MDR1. GBM cells (U87MG and U251MG), primary TGB105 cells, and mice xenografted with U87MG cells were treated with Ad-DKK3 or TMZ alone or in combination. Ad-DKK3 augmentation of the anti-tumor effects of TMZ was associated with reduced MDR1 expression in both in vivo and in vitro studies. The survival of Ad-DKK3-treated U87MG cells was inhibited and the expression of MDR1 was reduced. This was associated with the inhibition of Akt/NFκB but not of YB-1 via the JNK/c-Jun- or Akt pathway. Our results suggest that Ad-DKK3 regulates the expression of MDR1 via Akt/NFκB pathways and that it augments the anti-tumor effects of TMZ in GBM cells. (Tokushima University Institutional Repository) ● Metadata: 112895 (Link to Publication Site) ● Publication site (DOI): 10.1007/s11060-018-2894-5 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 29779087 ● Summary page in Scopus @ Elsevier: 2-s2.0-85047143200 (Tokushima University Institutional Repository: 112895, DOI: 10.1007/s11060-018-2894-5, PubMed: 29779087, Elsevier: Scopus)
11.	Aya Sato, Yoshifumi Mizobuchi, Kohhei Nakajima, Kenji Shono, Toshitaka Fujihara, Teruyoshi Kageji, Keiko Kitazato, Kazuhito Matsuzaki, Hideo Mure, Kazuyuki Kuwayama, Akiko Sumi, Hideyuki Saya, Oltea Sampetrean and Shinji Nagahiro : Blocking COX-2 induces apoptosis and inhibits cell proliferation via the Akt/survivin- and Akt/ID3 pathway in low-grade-glioma., Journal of Neuro-Oncology, Vol.132, No.2, 231-238, 2017. (Summary) Approximately half of surgically-treated patients with low-grade-glioma (LGG) suffer recurrence or metastasis. Currently there is no effective drug treatment. While the selective COX-2 inhibitor celecoxib showed anti-neoplastic activity against several malignant tumors, its effects against LGG remain to be elucidated. Ours is the first report that the expression level of COX-2 in brain tissue samples from patients with LGG and in LGG cell lines is higher than in the non-neoplastic region and in normal brain cells. We found that celecoxib attenuated LGG cell proliferation in a dose-dependent manner. It inhibited the generation of prostaglandin E2 and induced apoptosis and cell-cycle arrest. We also show that celecoxib hampered the activation of the Akt/survivin- and the Akt/ID3 pathway in LGGs. These findings suggest that celecoxib may have a promising therapeutic potential and that the early treatment of LGG patients with the drug may be beneficial. (Keyword) Animals / Apoptosis / Brain / Brain Neoplasms / Celecoxib / Cell Line, Tumor / Cell Proliferation / Cyclooxygenase 2 / Cyclooxygenase 2 Inhibitors / Enzyme Inhibitors / Female / Gene Expression Regulation, Neoplastic / Glioma / Humans / Inhibitor of Apoptosis Proteins / Inhibitor of Differentiation Proteins / Male / Mice / Mice, Inbred C57BL / Mice, Transgenic / Neoplasm Proteins / Proto-Oncogene Proteins c-akt / Signal Transduction (Tokushima University Institutional Repository) ● Metadata: 115523 (Link to Publication Site) ● Publication site (DOI): 10.1007/s11060-017-2380-5 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 28283800 ● Search Scopus @ Elsevier (PMID): 28283800 ● Search Scopus @ Elsevier (DOI): 10.1007/s11060-017-2380-5 (Tokushima University Institutional Repository: 115523, DOI: 10.1007/s11060-017-2380-5, PubMed: 28283800)

Proceeding of International Conference:

1.	Yoshiteru Tada, Toshitaka Fujihara, Kenji Shimada, Nobuaki Yamamoto, Hiroki Yamazaki, Yuishin Izumi, Masafumi Harada, Yasuhisa Kanematsu and Yasushi Takagi : Peri-ictal normal arterial spin labeling imaging in patients with seizures, 13 回アジア・オセアニアてんかん学会(13th AOEC), Jun. 2021.
2.	Kenji Shono, Izumi Yamaguchi, Toshitaka Fujihara, Keiko Kitazato, Kohhei Nakajima, Yoshifumi Mizobuchi, Hideo Mure, Kohhei Nakajima, Junichiro Satomi, Shinji Nagahiro and Yasushi Takagi : Celecoxib inhibits proliferation and induces apoptosis in glioma stem cells and an animal model of glioblastoma., 22ND ANNUAL SCIENTIFIC MEETING AND EDUCATION DAY OF THE SOCIETY FOR NEURO-ONCOLOGY, San Francisco, Nov. 2017.
3.	Junichiro Satomi, Yasuhisa Kanematsu, Masaaki Korai, Yuki Yamamoto, Nobuaki Yamamoto, Yoshifumi Mizobuchi, Hideo Mure, Yoshiteru Tada, Kohhei Nakajima, Toshiyuki Okazaki and Toshitaka Fujihara : Acute stroke management using image sharing on smart phones and tablet devices, 14TH CONGRESS OF THE WORLD FEDERATION OF INTERVENTIONAL AND THERAPEUTIC NEURORADIOLOGY, Budapest, Oct. 2017.

Proceeding of Domestic Conference:

1.	Toshitaka Fujihara, Yoshiteru Tada, Mai Azumi, Keijiro Hara, Kohhei Nakajima and Yasushi Takagi : Clinical characteristics and outcome of status epilepticus in patients with brain tumor, 日本脳神経外科学会第83回学術総会, Oct. 2024.
2.	Keijiro Hara, Mai Azumi, Toshitaka Fujihara, Kohhei Nakajima and Yasushi Takagi : 開頭摘出術を行った転移性脳腫瘍の術後成績, 日本脳神経外科学会第83回学術総会, Oct. 2024.
3.	Yoshiteru Tada, Toshitaka Fujihara, Masaaki Korai, Takeshi Miyamoto, Kenji Shimada and Yasushi Takagi : Outcome of nonconvulsive status epilepticus in patients with acute subarachnoid hemorrhage, 日本脳神経外科学会第83回学術総会, Oct. 2024.
4.	Toshitaka Fujihara, Kohhei Nakajima, Mai Azumi, Keijiro Hara and Yasushi Takagi : Tips for temporal lobectomy for malignant brain tumor of temporal lobe, 第29回日本脳腫瘍の外科学会, Oct. 2024.
5.	砂田陽二郎, Mai Azumi, Kohhei Nakajima, Toshitaka Fujihara, Keijiro Hara and Yasushi Takagi : 成人発症sellar Atypical Teratoid/Rhabdoid Tumorの一例, 第38回中国四国脳腫瘍研究会, Sep. 2024.
6.	Toshitaka Fujihara, Yoshiteru Tada, Kohhei Nakajima, Keijiro Hara, Mai Azumi and Yasushi Takagi : Epilepsy and perioperative seizures in surgical cases of supratentorial meningioma, 第57回日本てんかん学会学術集会, Sep. 2024.
7.	Yoshiteru Tada, Toshitaka Fujihara and Yasushi Takagi : 非けいれん性てんかん重積におけるASLでの陰性所見に関与する因子に関する検討, 第57回日本てんかん学会学術集会, Sep. 2024.
8.	Toshitaka Fujihara, Yoshiteru Tada and Yasushi Takagi : Clinical characteristics and treatment outcomes of VNS for elderly patients, 第37回日本老年脳神経外科学会, Apr. 2024.
9.	Yoshiteru Tada, Toshitaka Fujihara and Yasushi Takagi : 80歳以上の高齢者てんかんに対する迷走神経刺激療法の治療経験, 第18回日本てんかん学会中国・四国地方会, Feb. 2024.
10.	Yoshiteru Tada, Toshitaka Fujihara and Yasushi Takagi : Anatomical landmarks of temporal lobe and anterior temporal lobectomy, 第47回日本てんかん外科学会, Feb. 2024.
11.	Toshitaka Fujihara, Yoshiteru Tada and Yasushi Takagi : Clinical characteristics and treatment outcomes of VNS for elderly patients, 第47回日本てんかん外科学会, Feb. 2024.
12.	Yoshiteru Tada, Toshitaka Fujihara, Koichi Tomita, 飯田幸治 and Yasushi Takagi : Surgical training for frontal disconnection or lobectomy using fresh frozen cadavers, 第47回日本てんかん外科学会, Feb. 2024.
13.	Yoshiteru Tada, Toshitaka Fujihara and Yasushi Takagi : 非けいれん性てんかん重積におけるASLでの陰性所見に関与する因子に関する検討, 日本脳神経外科学会第82回学術総会, Oct. 2023.
14.	Toshitaka Fujihara, Kohhei Nakajima, Keijiro Hara, Mai Azumi, Taku Matsuda, Yoshiteru Tada and Yasushi Takagi : 脳腫瘍生検術におけるStealth Autoguideの初期使用経験, 日本脳神経外科学会第82回学術集会, Oct. 2023.
15.	Toshitaka Fujihara, Yoshiteru Tada and Yasushi Takagi : 高齢発症てんかんの特徴と治療経験, 第56回日本てんかん学会学術集会, Oct. 2023.
16.	Yoshiteru Tada, Toshitaka Fujihara, 泉千恵, 福田直也, Masahito Nakataki, Tatsuo Mori, Hiroki Yamazaki and Yasushi Takagi : 「誰も取り残さない」てんかんの医療費助成・福祉サービスの提供, 第56回日本てんかん学会学術集会, Oct. 2023.
17.	Kohhei Nakajima, Mai Azumi, Toshitaka Fujihara, Keijiro Hara and Yasushi Takagi : Sellar atypical teratoid/rhabdoid tumor の1例, 第28回日本脳腫瘍の外科学会, Sep. 2023.
18.	手島奈津美, Mai Azumi, Kohhei Nakajima, Tomohiro Matsuda, Izumi Yamaguchi, Toshitaka Fujihara, Shu Sogabe, Keijiro Hara and Yasushi Takagi : 術後管理に難渋した頭蓋咽頭腫の1例, 第95回日本脳神経外科学会中国四国支部学術集会, Apr. 2023.
19.	Tatsuo Mori, Yoshiteru Tada, Masahito Nakataki, Takahiro Tayama, Aya Gohji, Yoshihiro Touda, Toshitaka Fujihara, Hiroki Yamazaki and Kenji Mori : 徳島大学病院てんかんセンターにおけるトランジションの現状と今後の課題, 第10回全国てんかんセンター協議会総会栃木大会 2023, Mar. 2023.
20.	Toshitaka Fujihara, Yoshiteru Tada, Kohhei Nakajima, 手島奈津美 and Yasushi Takagi : 深部電極留置におけるStealth Autoguideの初期使用経験:Posterior quadrantectomyを行った薬剤抵抗性てんかんの1例, 第17回日本てんかん学会中国・四国地方会, Feb. 2023.
21.	Yoshiteru Tada, Masahito Nakataki, Tatsuo Mori, Toshitaka Fujihara, Aya Gohji, Hiroki Yamazaki, 泉千恵, 高尾里沙, 多田雅美, 阿部修司, Kenji Mori and Yasushi Takagi : 地方におけるてんかん支援拠点病院の役割, 第10回全国てんかんセンター協議会, Feb. 2023.
22.	Toshitaka Fujihara, Yoshiteru Tada and Yasushi Takagi : てんかん外科へのアクセス困難な地域における診療支援, 第10回全国てんかんセンター協議会, Feb. 2023.
23.	Yoshiteru Tada, Toshitaka Fujihara, 板東康司, 山本陽子 and Yasushi Takagi : Five cases of vagus nerve stimulation for drug-resistant status epilepticus, 第46回日本てんかん外科学会, Jan. 2023.
24.	Toshitaka Fujihara, Yoshiteru Tada, 板東康司 and Yasushi Takagi : An effective case of posterior quadrantectomy for drug resistant epilepsy after brain tumor surgery, 第46回日本てんかん外科学会, Jan. 2023.
25.	Mai Azumi, Toshitaka Fujihara, Keijiro Hara, Kohhei Nakajima, Yoshifumi Mizobuchi and Yasushi Takagi : Examination about the predictors of outcome at discharge in postoperative brain tumor patients admitted to the intensive care units, 日本脳神経外科学会第81回学術総会, Sep. 2022.
26.	Yoshiteru Tada, Toshitaka Fujihara, Kenji Shimada, Yasuhisa Kanematsu and Yasushi Takagi : Seizure types associated with finding of arterial spin labeling and diffusion-weighted imaging, 第55回日本てんかん学会学術集会, Sep. 2022.
27.	Keijiro Hara, Yoshifumi Mizobuchi, Mai Azumi, Shu Sogabe, Toshitaka Fujihara, Kohhei Nakajima and Yasushi Takagi : Hyper vascularityを呈した松果体部腫瘍の1例, 第93回日本脳神経外科学会中国四国支部学術集会, Apr. 2022.
28.	平野愛子, 北村愛里, 重根裕代, 川原みゆき, Toshitaka Fujihara, Yoshiteru Tada, Kenji Mori and Yasushi Takagi : 長時間ビデオ脳波モニタリング実施時の発作時観察力向上のための取り組み∼発作観察時のビデオ作成発作時対応のシミュレーションの実施∼., , Mar. 2022.
29.	高尾里沙, 多田雅美, 安部修司, Masahito Nakataki, Tatsuo Mori, Toshitaka Fujihara, Yoshiteru Tada, Hiroki Yamazaki and Kenji Mori : てんかん相談における徳島県の現状の把握と今後の課題., 第9回全国てんかんセンター協議会総会鹿児島大会, Mar. 2022.
30.	Yoshiteru Tada, Masahito Nakataki, Tatsuo Mori, Toshitaka Fujihara, Aya Gohji, Hiroki Yamazaki, 高尾里沙, 泉千恵, 多田雅美, 安部修司 and Kenji Mori : 今後の徳島県におけるてんかん地域診療連携整備事業の展望について, 第9回全国てんかんセンター協議会総会, Mar. 2022.
31.	Yasuhisa Kanematsu, Toshitaka Fujihara, Kenji Shimada, Yoshiteru Tada and Yasushi Takagi : 外傷性内頚動脈海綿静脈洞瘻による静脈環流障害から非けいれん性てんかん重積をきたした一例, 第45回日本脳神経外傷学会, Feb. 2022.
32.	Toshitaka Fujihara, Yoshiteru Tada, 片桐匡弥, 香川幸太, 飯田幸治 and Yasushi Takagi : 比較的長時間持続する両側口角のけいれんを主とする薬剤抵抗性てんかんに対し迷走神経刺激療法を施行した1例, 第16回日本てんかん学会中国・四国地方会, Feb. 2022.
33.	Toshitaka Fujihara, Yoshiteru Tada and Yasushi Takagi : Vegas nerve stimulation revision at pulse generator re-implantation; a case report, The 45th Annual Meeting of Epilepsy Surgery Society of Japan, Jan. 2022.
34.	Yoshiteru Tada, Toshitaka Fujihara, Yoshihiro Tsuruo, 飯田幸治 and Yasushi Takagi : Surgical training for hemispherectomy using fresh frozen cadavers, 第45回日本てんかん外科学会, Jan. 2022.
35.	Toshitaka Fujihara, Yoshiteru Tada, Yoshifumi Mizobuchi, Kohhei Nakajima, Keijiro Hara, Mai Azumi and Yasushi Takagi : Epilepsy and perioperative seizure management in surgical cases of supratentorial meningioma, 日本脳神経外科学会第80回学術総会, Oct. 2021.
36.	Yoshiteru Tada, Toshitaka Fujihara, Yoshihiro Tsuruo and Yasushi Takagi : Surgical training for epilepsy surgery using fresh frozen cadavers, NMC Case Report Journal, Oct. 2021.
37.	Kohhei Nakajima, Yoshifumi Mizobuchi, Toshitaka Fujihara, Mai Azumi and Yasushi Takagi : 中枢神経原発悪性リンパ腫に対する大量メトトレキサート維持療法の意義, NMC Case Report Journal, Oct. 2021.
38.	Mai Azumi, Takeshi Miyamoto, Toshitaka Fujihara, Kohhei Nakajima, Keijiro Hara, Yoshifumi Mizobuchi and Yasushi Takagi : 特発性頭蓋内圧亢進様の症状のみで発症した小児脳腫瘍の1例, 第35回中国四国脳腫瘍研究会, Sep. 2021.
39.	Yoshiteru Tada, Toshitaka Fujihara, Yoshihiro Tsuruo, 飯田幸治 and Yasushi Takagi : Surgical training for hemispherectomy using fresh frozen cadavers, 第54回日本てんかん学会学術集会, Sep. 2021.
40.	Yoshiteru Tada, Toshitaka Fujihara, Yuichi Satoh, 飯田幸治 and Yasushi Takagi : 2期的に半球離断術を施行した成人片側巨脳症の1例, 第15回日本てんかん学会中国・四国地方会, Feb. 2021.
41.	Toshitaka Fujihara, Yoshiteru Tada, Kenji Shimada, Yasuhisa Kanematsu and Yasushi Takagi : 内頚動脈海綿静脈洞瘻に急性症候発作重積を合併した1例, 第14回日本てんかん学会中国・四国地方会, Feb. 2020.
42.	Toshitaka Fujihara, Yoshiteru Tada, Mai Azumi and Yasushi Takagi : 海馬からのてんかん性放電が乏しかった海馬硬化症の1例, 第7回全国てんかんセンター協議会広島大会, Feb. 2020.
43.	Yoshiteru Tada, Yoshihiro Touda, Masahito Nakataki, Toshitaka Fujihara, 森達夫, Aya Gohji, 飯田幸治, Kenji Mori and Yasushi Takagi : 徳島県におけるてんかん地域診療連携整備事業の活動状況, 第7回全国てんかんセンター協議会広島大会, Feb. 2020.
44.	Yoshiteru Tada, Toshitaka Fujihara, 香川幸太, 片桐匡弥, 瀬山剛, 飯田幸治 and Yasushi Takagi : 遠隔てんかん症例検討会による薬剤抵抗性側頭葉てんかん治療方針の決定について, 第43回日本てんかん外科学会, Jan. 2020.
45.	Toshitaka Fujihara, Yoshiteru Tada, Yasuhisa Kanematsu and Yasushi Takagi : Wadatestにて言語優位半球を同定できなかった薬剤抵抗性側頭葉てんかんの一例, 第43回日本てんかん外科学会, Jan. 2020.
46.	Masahito Nakataki, Hiroaki Edo, Yoshiteru Tada, Yoshihiro Touda, Toshitaka Fujihara, Tatsuo Mori, Aya Gohji, Kenji Mori and Tetsuro Ohmori : てんかん発作や精神症状と関連しない生活の質, 第53回日本てんかん学会学術集会, Nov. 2019.
47.	Toshitaka Fujihara, Yoshiteru Tada, Yoshifumi Mizobuchi, Kohhei Nakajima, Mai Azumi and Yasushi Takagi : 脳腫瘍手術における周術期抗てんかん薬使用と術後発作抑制効果についての検討, 第53回日本てんかん学会学術集会, Oct. 2019.
48.	Yoshiteru Tada, Yoshihiro Touda, Masahito Nakataki, Toshitaka Fujihara, Tatsuo Mori, Aya Gohji, 飯田幸治, Kenji Mori and Yasushi Takagi : 徳島県におけるてんかん地域診療連携整備事業の紹介, 第53回日本てんかん学会学術集会, Oct. 2019.
49.	Hiroshi Kagusa, Yoshifumi Mizobuchi, Toshitaka Fujihara, Kohhei Nakajima and Yasushi Takagi : 眼窩内に転移した子宮頚癌の1例, 日本脳神経外科学会第78回学術集会, Oct. 2019.
50.	Kohhei Nakajima, Toshitaka Fujihara, Yoshifumi Mizobuchi and Yasushi Takagi : 当院における転移性脳腫瘍に対する術後放射線療法の検討, 日本脳神経外科学会第78回学術集会, Oct. 2019.
51.	Yoshiteru Tada, Toshitaka Fujihara, Kohhei Nakajima, Mai Azumi and Yasushi Takagi : 高齢発症てんかんの臨床的特徴, 日本脳神経外科学会第78回学術集会, Oct. 2019.
52.	Toshitaka Fujihara, Yoshifumi Mizobuchi, Kohhei Nakajima, Mai Azumi, Yoshiteru Tada and Yasushi Takagi : Perioperative prophylactic antiepileptic drug use and postoperative seizure in brain tumor surgery, Neurologia Medico-Chirurgica, Oct. 2019.
53.	Kohhei Nakajima, Toshitaka Fujihara, Yoshifumi Mizobuchi and Yasushi Takagi : 中枢神経原発性悪性リンパ腫に対する大量メトトレキサート維持療法の治療成績, 第36回日本脳腫瘍学会学術集会, Dec. 2018.
54.	Kohhei Nakajima, Toshitaka Fujihara, Yoshifumi Mizobuchi and Yasushi Takagi : 穿刺様頭痛で発見された中枢神経アスペルギルス症の1例, 第46回日本頭痛学会総会, Nov. 2018.
55.	Yoshiteru Tada, Toshitaka Fujihara, Kohhei Nakajima, Kenji Mori and Yasushi Takagi : 高齢発症てんかんの臨床的特徴，新規抗てんかん薬の効果, 日本脳神経外科学会第77回学術総会, Oct. 2018.
56.	Toshitaka Fujihara, Yoshifumi Mizobuchi, Kohhei Nakajima, Toshiyuki Okazaki, Hideo Mure and Yasushi Takagi : 膠芽腫におけるDKK3遺伝子導入による薬剤排泄ポンプの発現抑制の意義, 日本脳神経外科学会第77回学術総会, Oct. 2018.
57.	鹿草宏, Yoshifumi Mizobuchi, Toshitaka Fujihara, Kohhei Nakajima and Yasushi Takagi : 慢性硬膜下血腫の手術方法の検討, 日本脳神経外科学会第77回学術総会, Oct. 2018.
58.	Kohhei Nakajima, Toshitaka Fujihara, Yoshifumi Mizobuchi and Yasushi Takagi : 当院における中枢神経原発悪性リンパ腫に対する大量メトトレキサート維持療法の治療成績, 日本脳神経外科学会第77回学術総会, Oct. 2018.
59.	Yoshifumi Mizobuchi, Kohhei Nakajima, Toshitaka Fujihara, Shinji Nagahiro and Yasushi Takagi : 顔面痙攣に対する手術手技 "shelter method" の有効性と長期予後, 日本脳神経外科学会第77回学術総会, Oct. 2018.
60.	Shoichi Hatada, 小山広士, Toshitaka Fujihara, Kohhei Nakajima, Yoshifumi Mizobuchi and Yasushi Takagi : 短期間で出血を繰り返した多発脳病変の1例, 第32回中国四国脳腫瘍研究会, Sep. 2018.
61.	Yoshiteru Tada, Toshitaka Fujihara, Aya Gohji, Tatsuo Mori, Yoshihiro Touda, Kenji Mori, 飯田幸治, Junichiro Satomi and Yasushi Takagi : 術前精査中にバルブロ酸の追加が著効したrolandic crtical dysplasiaに1例, 第41回日本てんかん外科学会, Jan. 2018.
62.	Toshitaka Fujihara, Yoshiteru Tada, Kohhei Nakajima, Hideo Mure, Masafumi Harada, Junichiro Satomi and Shinji Nagahiro : 非痙攣性てんかん重積診断におけるArterial Spin Labeling法の有用性, 第51回日本てんかん学会年次学術集会, Nov. 2017.
63.	Toshitaka Fujihara, Yoshiteru Tada, Kohhei Nakajima, Hideo Mure, Masafumi Harada, Junichiro Satomi and Shinji Nagahiro : 当院で経験した非痙攣性てんかん重積症例の検討, 日本脳神経外科学会第76回学術総会, Oct. 2017.
64.	Toshitaka Fujihara, Yoshiteru Tada, Kohhei Nakajima, Hideo Mure, 飯田幸治 and Shinji Nagahiro : 同側の未破裂中大脳動脈瘤を合併した左海馬硬化症による難治性内側側頭葉てんかんの一例, 第11回てんかん学会中国・四国地方会, Feb. 2017.

Et cetera, Workshop:

1.	Mai Azumi, Kohhei Nakajima, Toshitaka Fujihara, Keijiro Hara and Yasushi Takagi : リツシマブ併用大量療法が奏功した難治性中枢神経原発悪性リンパ腫の1例, 第37回中四国脳腫瘍研究会, Sep. 2023.
2.	Tatsuya Haboshi, Yoshiteru Tada, Toshitaka Fujihara, 亘雄也, Kohhei Nakajima and Yasushi Takagi : 前方脳梁離断術を施行した成人難治性てんかんの2例, 第43回徳島脳神経外科談話会, Dec. 2017.
3.	Toshitaka Fujihara, Yoshiteru Tada and Shinji Nagahiro : 当院で経験した非痙攣性てんかん重積症例の検討, 第4回徳島脳神経疾患談話会, Mar. 2017.

Grants-in-Aid for Scientific Research (KAKEN Grants Database @ NII.ac.jp)

Search by Researcher Number (90551060)

Designated Assistant Professor : Fujihara, Toshitaka

Research

Field of Study

Subject of Study

Book / Paper

Academic Paper (Judged Full Paper):

Proceeding of International Conference:

Proceeding of Domestic Conference:

Et cetera, Workshop:

Grants-in-Aid for Scientific Research (KAKEN Grants Database @ NII.ac.jp)